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thrombocytopenia, hepatomegaly, and 
recent exposure to ticks. Although 
Amblyomma americanum, the main 
known vector of E. chaffeensis, has 
not been reported in Venezuela, Rhipi-
cephalus sanguineus and A.  cajen-
nense are abundant in rural areas of 
Venezuela; their ability to be vectors 
should be investigated.
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Resource 
Allocation during 
an Inﬂ  uenza 
Pandemic 
To the Editor: Planning for pan-
demic inﬂ  uenza is accepted as an es-
sential healthcare service and has 
included creation of national and in-
ternational antiviral drug stockpiles 
and novel approaches to emergency 
vaccine development (1). The ef-
fectiveness of these strategies in a 
pandemic may be substantial but is 
unknown. More certain is that effec-
tive management of severe and com-
plicated inﬂ  uenza will reduce deaths 
and that demand will exceed available 
treatment resources (2). Appropri-
ate allocation of treatment resources 
is therefore essential, perhaps more 
important than any speciﬁ  c treatment 
such as administering antiviral medi-
cation to symptomatic patients. Re-
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Figure. Peripheral blood smears (buffy-coat preparation) showing variable-sized basophilic 
inclusions (arrows) in mononuclear cells from a 9-year-old boy with human monocytic 
ehrlichiosis, Carabobo, Venezuela. Dip Quick (Jorgensen Laboratories, Inc., Loveland, 
CO, USA) staining; magniﬁ  cation ×1,000.LETTERS
source allocation requires the follow-
ing: 1) making clear societal decisions 
on the goals for healthcare resources; 
2) conducting operational research to 
develop an evidence base to support 
the achievement of these goals; and 
3) developing systems to capture and 
learn from new information in a pan-
demic to facilitate modiﬁ  cation of the 
response as the characteristics of the 
pandemic emerge. Most societies have 
not yet addressed the ﬁ  rst issue fully. 
In the United Kingdom, a Department 
of Health consultation on planning 
critical care during emergencies cites 
“the underpinning principle of provid-
ing the greatest good for the greatest 
number of people during the course 
of an emergency” and thus appears to 
support a capacity-to-beneﬁ  t approach 
(3). Similarly, triage criteria developed 
in Canada, based on the Sequential Or-
gan Failure Assessment (SOFA) score, 
exclude those persons believed to be 
too ill or otherwise unlikely to beneﬁ  t 
from critical care (4). Even more im-
portant for most severely ill patients, 
however, will be deciding whether to 
admit them to the hospital at all. The 
UK pandemic-planning criteria cur-
rently recommend a scoring system 
for hospital admission based on an 
assessment of poor outcome rather 
than on capacity to beneﬁ  t (2). Indeed, 
age >85 years and severe underlying 
cognitive impairment, which would 
rule out admission to critical care in 
Canada, would strongly favor admis-
sion to hospital care in the United 
Kingdom, the opposite of the situation 
for a younger cognitively intact person 
with similar disease severity. If tools 
are to be developed to support triage 
at all stages of the patient pathway  in 
a pandemic, societies must consider 
the ethical issues raised (4,5), debate 
them, and take a position on the values 
that should underpin decision making 
in a pandemic.
Even when clear societal goals 
are established, much work remains 
to ensure that the healthcare commu-
nity  is equipped to steer healthcare 
resources to deliver these effectively 
(6). Community-acquired pneumonia 
has been used as a surrogate for inﬂ  u-
enza to test predictive scoring systems 
for assessing severity and assisting tri-
age decisions (7). Seasonal inﬂ  uenza 
epidemics would provide the most re-
alistic setting available, in particular, 
if protocols were in place to test crite-
ria when a relatively severe inﬂ  uenza 
season occurs. In addition to identify-
ing criteria for setting priorities within 
inﬂ   uenza management, such testing 
will need to consider the balance of 
resources between inﬂ  uenza treatment 
and treatment of other usual nonin-
ﬂ   uenza conditions that will require 
emergency care during the pandemic. 
Decisions that must be made during a 
pandemic are complex, varying from 
when to stop major elective surgery 
so critical care capacity can be opened 
up, to how to triage those who have 
experienced major trauma and those 
with inﬂ  uenza. These decisions could 
differ from those same decisions made 
outside a pandemic, and an adequate 
evidence base is needed if they are to 
be of good quality.
The third component of our 
preparation for optimally deploying 
standard care in a pandemic is being 
able to change our approach quickly 
as new knowledge emerges. In the 
so-called Spanish inﬂ  uenza pandemic 
of 1918–19, the unfamiliar clinical 
course meant that inﬂ  uenza was not 
even considered when the ﬁ  rst cases 
appeared (8), and expectations had to 
be revised concerning who was most 
vulnerable and at what stage in their 
clinical course they were most at risk. 
Therefore, healthcare profession-
als must develop and test the public 
health infrastructure to capture pa-
tient factors associated with outcome 
and treatment response during a pan-
demic and feed this information back 
into clinical practice rapidly and reli-
ably, as occurred during the epidemic 
of severe acute respiratory syndrome 
(9). International collaboration will be 
important for sharing this work (10) 
and developing useful tools early in a 
pandemic. Having recognized the risk 
for pandemic inﬂ  uenza, we must now 
complement the research into novel 
inﬂ  uenza treatments by addressing our 
knowledge gap on how best to use our 
resources to deliver optimal clinical 
care in the management of inﬂ  uenza 
guided by effective clinical surveil-
lance. 
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Novel Relapsing 
Fever Spirochete in 
Bat Tick
To the Editor: Tick-borne relaps-
ing fever in western North America is 
a zoonosis caused by spirochetes in 
the genus Borrelia that are transmit-
ted by argasid ticks of the genus Or-
nithodoros (1). Human disease occurs 
in many focal areas and is associated 
with infections of Borrelia hermsii, 
B. turicatae, and possibly B. parkeri 
(2,3). Although the ecologic param-
eters that maintain B. hermsii and B. 
turicatae differ, human infections usu-
ally occur in rustic cabins (B. hermsii) 
and caves (B. turicatae) inhabited by 
ticks and their terrestrial vertebrate 
hosts (1). Recently, Gill et al. (4) pro-
vided evidence that the argasid bat 
tick,  Carios kelleyi, feeds upon hu-
mans. Subsequently, Loftis et al. (5) 
used PCR analysis and DNA sequenc-
ing to detect in C. kelleyi an unidenti-
ﬁ  ed Borrelia species that was closely 
related to B. turicatae and B. parkeri. 
We report the partial molecular char-
acterization of another novel tick-
borne relapsing fever spirochete in C. 
kelleyi, which expands our knowledge 
for this group of pathogenic spiro-
chetes and their potential vertebrate 
hosts and tick vectors.
C. kelleyi were collected Au-
gust 18, 2005, from a house in Jones 
County, Iowa, built in 1857. Bats had 
been excluded from the attic since 
1992. Nine months before ticks were 
collected, bats were prevented from 
roosting under the eaves. DNA was 
extracted from 31 nymphal C. kel-
leyi, as described previously (6). For 
each tick, regions of the glpQ, ﬂ  aB, 
and 16S rRNA genes were ampliﬁ  ed 
and sequenced as described (3,7,8). 
Sequences were assembled by using 
the SeqMan program in the Lasergene 
software package (DNASTAR, Madi-
son, WI, USA).
Fourteen (45.1%) of 31 ticks were 
positive by PCR for >1 of the genes 
tested. Partial DNA sequences were 
determined from tick no. 16, for which 
amplicons for all 3 genes were ob-
tained. The partial ﬂ  aB sequence had 
4 bases different from the 300-base 
sequence (98.66% identity) reported 
previously (GenBank accession no. 
AY763104) for another Borrelia  sp. 
found in C. kelleyi (5). We constructed 
a 1,992-bp concatenated sequence 
that contained 1,273 bp of the 16S 
rRNA, 351 bp of ﬂ  aB, and 368 bp of 
glpQ. This concatenated sequence was 
aligned with homologous, trimmed 
DNA sequences of the same length ob-
tained from representative full-length 
sequences determined previously 
for  B. hermsii,  B. turicatae, and B. 
parkeri (3,9) (Figure). This C. kelleyi 
spirochete was more closely related to 
B. turicatae and B. parkeri than to B. 
hermsii but was clearly distinct from 
all 3 species (DNA sequence identities 
of 98.89%, 98.75%, and 95.98% to B. 
turicatae, B. parkeri, and B. hermsii, 
respectively).
A  glpQ amplicon from another 
nymphal tick (no. 3) was sequenced 
(GenBank accession no. EF688578) 
and was unique in the database; it was 
also considerably different from the 
glpQ sequence determined from tick 
16, with 325 of 368 bases matching 
(88.3% identity). The Borrelia glpQ se-
quence from tick 3 had 85.1%–89.1% 
identity compared with glpQ sequenc-
es from B. hermsii, B. turicatae, and B. 
parkeri. This ﬁ  nding suggests the pres-
ence of at least 2 relapsing fever group 
spirochetes in C. kelleyi that await fur-
ther characterization.
We found a novel Borrelia in bat 
ticks that is closely related to, but dis-
tinct from, the other known species of 
tick-borne relapsing fever spirochetes 
in North America. The human health 
implications of the new relapsing fever 
group spirochete are not yet known. 
The willingness of C. kelleyi to feed 
on humans and the fact that infection 
with bacteria closely related to true 
relapsing fever spirochetes occurs in 
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Figure. Phylogram comparing the novel spirochete in the bat tick Carios kelleyi with 
Borrelia parkeri,  B. turicatae, and B. hermsii based on the concatenated partial 16S 
rRNA-ﬂ  aB-glpQ DNA sequences in the Carios spirochete (1,992 bp total) (produced with 
ClustalV software from DNASTAR [Madison, WI, USA]). Scale bar represents the number 
of base substitutions per 100 aligned bases. GenBank accession numbers for the C. kelleyi 
spirochete sequences used to construct the tree are EF688575, EF688576, and EF688577. 
Spiro, spirochete.